Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Set to Profit from FDA’s MRTP Pathway Announcement

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator with technology that has demonstrated its ability to enhance the oral delivery of nicotine, is positioned to benefit from the FDA’s recent announcement that it had authorized the marketing of eight smokeless tobacco products through the modified-risk, tobacco-product (“MRTP”) pathway ( An article discussing the company reads, “The FDA approval of the ‘modified risk’ claims was made after reviewing scientific evidence submitted by the manufacturer of the products. The approvals, which are product specific and expire after five years, do not mean the products come with no health risks. Nicotine-based products are addictive and may, according to some studies, induce the onset of cardiovascular, respiratory and gastrointestinal disorders. . . . The patented DehydraTECH(TM) drug-delivery platform mitigates a serious limitation to nicotine ingestion. The human GI system struggles to process nicotine in the forms in which it is presently offered, one reason why there are currently no edible, nicotine, manufactured products available, although some natural foods — eggplant, green pepper, potato, tomato — do contain nicotine. However, DehydraTECH employs a delivery mechanism that improves the bioabsorption and bioavailability of many ingestible substances, as well as their taste and smell, by using lipophilic agents. Application of the technology extends beyond nicotine to nonpsychoactive cannabinoids, vitamins and nonsteroidal anti-inflammatory drugs (NSAIDs).”

To view the full article, visit

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks. Bookmark the permalink.

Comments are closed.